258 filings
Page 4 of 13
8-K
clzjug
4 Jun 20
Departure of Directors or Certain Officers
5:17pm
8-K
lmtso7z
11 May 20
Acceleron Reports First Quarter 2020 Operating and Financial Results
4:10pm
8-K
df0tn
5 May 20
Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
5:06pm
DEFA14A
21arxe93 wgjk25
16 Apr 20
Additional proxy soliciting materials
4:35pm
8-K
8qyv5mwt0 8dd
9 Apr 20
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
5:26pm
8-K
5nssw
7 Apr 20
Departure of Directors or Certain Officers
4:39pm
8-K
isocw35m482m3oq29a
6 Apr 20
Other Events
8:41am
8-K
okj hronna08wll
9 Mar 20
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
4:09pm
S-8
yjc3pl 6rje
27 Feb 20
Registration of securities for employees
4:22pm
8-K
jqs tmd332
27 Feb 20
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
4:10pm
8-K
c6aes
27 Jan 20
Other Events
4:14pm
8-K
zrel9xpa y6u4fznd
23 Jan 20
Departure of Directors or Certain Officers
4:20pm
8-K
kx1mfoh
13 Dec 19
Other Events
4:35pm
8-K
k1upna61po9afsvkiz43
9 Dec 19
Other Events
8:04am
8-K
9pukxk 2synaz69j8
6 Dec 19
Departure of Directors or Certain Officers
5:26pm
8-K
5ch klivw8j
8 Nov 19
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients
5:27pm